CTLA4 and neoplasm: By contrast, mice that had previously achieved complete remission following dual IRE + anti-CTLA-4 therapy were 100% protected from secondary tumor challenge, and showed significant survival advantage over mice not receiving IRE therapy (Fig. 8b, 9/9 mice).